CYMABAY THERAPEUTICS INC OM
(NASDAQ:CBAY)
$32.48
0[0.00%]
At close: Mar 21
$32.48
0[0.00%]
After Hours: 4:20PM EDT
CymaBay Therapeutics (CBAY) was acquired by Gilead Sciences (GILD) on Friday, March 22, 2024 for $4.3B paid in cash
Consensus Rating1
Neutral
Highest Price Target1
$32.50
Lowest Price Target1
$12.00
Consensus Price Target1
$19.37

CYMABAY THERAPEUTICS INC OM Stock (NASDAQ:CBAY), Analyst Ratings, Price Targets, Predictions

CYMABAY THERAPEUTICS INC OM has a consensus price target of $19.37, established from looking at the 54 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Leerink Partners, and LifeSci Capital on February 29, 2024, February 20, 2024, and February 14, 2024. With an average price target of $21.67 between HC Wainwright & Co., Leerink Partners, and LifeSci Capital, there's an implied -33.29% downside for CYMABAY THERAPEUTICS INC OM from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Nov 23
1
3
Dec 23
1
Feb
11
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Leerink Partners
LifeSci Capital
UBS
Piper Sandler

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for CYMABAY THERAPEUTICS INC OM

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/29/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%HC Wainwright & Co.
Ed Arce
→ $32.5ReiteratesNeutral → NeutralGet Alert
02/20/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%Leerink Partners
Thomas Smith
→ $32.5DowngradeOutperform → Market PerformGet Alert
02/14/2024CBAYBuy Now
CymaBay Therapeutics
$32.48LifeSci Capital
Cory Jubinville
DowngradeOutperform → Market PerformGet Alert
02/14/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%UBS
Eliana Merle
$25 → $32.5DowngradeBuy → NeutralGet Alert
02/14/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%Piper Sandler
Yasmeen Rahimi
$33 → $32.5DowngradeOverweight → NeutralGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%B. Riley Securities
Mayank Mamtani
$29 → $32.5DowngradeBuy → NeutralGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.48BTIG
Julian Harrison
DowngradeBuy → NeutralGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.48HC Wainwright & Co.
Ed Arce
DowngradeBuy → NeutralGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%Raymond James
Steven Seedhouse
$32.5 → $32.5DowngradeStrong Buy → Market PerformGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.480.06%Cantor Fitzgerald
Kristen Kluska
→ $32.5DowngradeOverweight → NeutralGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
$32.48JonesTrading
Sean Kim
DowngradeBuy → HoldGet Alert
02/12/2024CBAYBuy Now
CymaBay Therapeutics
$32.48William Blair
Andy Hsieh
DowngradeOutperform → Market PerformGet Alert
12/15/2023CBAYBuy Now
CymaBay Therapeutics
$32.48-13.79%HC Wainwright & Co.
Ed Arce
$24 → $28MaintainsBuyGet Alert
11/08/2023CBAYBuy Now
CymaBay Therapeutics
$32.48-26.11%Cantor Fitzgerald
Kristen Kluska
$23 → $24MaintainsOverweightGet Alert
11/08/2023CBAYBuy Now
CymaBay Therapeutics
$32.48-26.11%HC Wainwright & Co.
Ed Arce
$21 → $24MaintainsBuyGet Alert
11/08/2023CBAYBuy Now
CymaBay Therapeutics
$32.484.68%Raymond James
Steven Seedhouse
$33 → $34MaintainsStrong BuyGet Alert
11/06/2023CBAYBuy Now
CymaBay Therapeutics
$32.481.6%Piper Sandler
Yasmeen Rahimi
$19 → $33MaintainsOverweightGet Alert
09/26/2023CBAYBuy Now
CymaBay Therapeutics
$32.48-23.03%UBS
Eliana Merle
$18 → $25MaintainsBuyGet Alert
09/08/2023CBAYBuy Now
CymaBay Therapeutics
$32.48-32.27%B. Riley Securities
Mayank Mamtani
$16 → $22MaintainsBuyGet Alert

FAQ

Q

What is the target price for CYMABAY THERAPEUTICS INC OM (CBAY)?

A

The latest price target for CYMABAY THERAPEUTICS INC OM (NASDAQ: CBAY) was reported by HC Wainwright & Co. on February 29, 2024. The analyst firm set a price target for $32.50 expecting CBAY to rise to within 12 months (a possible 0.06% upside). 41 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for CYMABAY THERAPEUTICS INC OM (CBAY)?

A

The latest analyst rating for CYMABAY THERAPEUTICS INC OM (NASDAQ: CBAY) was provided by HC Wainwright & Co., and CYMABAY THERAPEUTICS INC OM reiterated their neutral rating.

Q

When was the last upgrade for CYMABAY THERAPEUTICS INC OM (CBAY)?

A

There is no last upgrade for CYMABAY THERAPEUTICS INC OM.

Q

When was the last downgrade for CYMABAY THERAPEUTICS INC OM (CBAY)?

A

The last downgrade for CYMABAY THERAPEUTICS INC OM happened on February 20, 2024 when Leerink Partners changed their price target from N/A to $32.5 for CYMABAY THERAPEUTICS INC OM.

Q

When is the next analyst rating going to be posted or updated for CYMABAY THERAPEUTICS INC OM (CBAY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CYMABAY THERAPEUTICS INC OM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CYMABAY THERAPEUTICS INC OM was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.

Q

Is the Analyst Rating CYMABAY THERAPEUTICS INC OM (CBAY) correct?

A

While ratings are subjective and will change, the latest CYMABAY THERAPEUTICS INC OM (CBAY) rating was a reiterated with a price target of $0.00 to $32.50. The current price CYMABAY THERAPEUTICS INC OM (CBAY) is trading at is $32.48, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.